Tech Company Financing Transactions
Synchroneuron Funding Round
Synchroneuron closed a $20 million Series B financing round on 7/2/2014. Investors included Morningside Group.
Transaction Overview
Company Name
Announced On
7/2/2014
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series B
Investors
Morningside Group (Isaac Cheng)
Proceeds Purpose
This funding supports the continued development of SNC-102, a new formulation of acamprosate calcium currently being studied in a Phase 2 trial to treat moderate-to-severe tardive dyskinesia (TD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1188 Centre St.
Newton, MA 02466
USA
Newton, MA 02466
USA
Phone
Website
Email Address
Overview
Synchroneuron Inc., a Waltham, Mass.-based biopharmaceutical company that develops new therapies for tardive dyskinesia (TD) and other related movement disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Kerns
Chief Financial Officer
Marc Cote
Chief Scientific Officer
Barry Fogel
VP - Bus. Development
Kei-Lai Fong
Browse more venture capital transactions:
Prev: 7/2/2014: Terascala venture capital transaction
Next: 7/3/2014: GridPoint venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs